Advancing Treatment Strategies in Ovarian Cancer: The Evolving Role of Antibody-Drug Conjugates

home / around-the-practice / advancing-treatment-strategies-in-ovarian-cancer-the-evolving-role-of-antibody-drug-conjugates

Leslie Randall, MD; Marion E. Cole, MD; Asim Farooq, MD, and Mallorie Haba, FNP, discuss how antibody-drug conjugates are transforming treatment strategies in recurrent ovarian cancer by offering new options for patients with platinum-resistant disease, emphasizing molecular testing, treatment sequencing, side effect management—particularly ocular toxicities—and the importance of patient-centered care.

Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity

EP. 1: Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity

Leslie Randall, MD ;Marion E. Cole, MD;Asim Farooq, MD;Mallorie Haba, FNP
May 30th 2025

Panelists discuss how treatment approaches differ between platinum-sensitive and platinum-resistant ovarian cancer patients, emphasizing the use of platinum doublets and maintenance therapies in sensitive cases versus the limited options historically available for resistant cases.

The Role of Molecular Testing in Ovarian Cancer Care

EP. 2: The Role of Molecular Testing in Ovarian Cancer Care

Leslie Randall, MD ;Marion E. Cole, MD;Asim Farooq, MD;Mallorie Haba, FNP
May 30th 2025

Panelists discuss how molecular testing strategies prioritize BRCA and HRD status at diagnosis while incorporating folate receptor alpha and other biomarkers in the recurrent setting to guide treatment decisions and clinical trial eligibility.